Studies
AHCC® Association is dedicated to providing the latest information on AHCC® mushroom extract to ensure consumers understand what AHCC® is, how it works, news articles, and studies on its clinically-proven efficacy in addressing a wide range of ailments.
Clinical Studies by Condition
Overview
Read More
Published Human Studies
AHCC® Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer
Frontiers in Immunology
Can AHCC be used in the treatment of head and neck cancer patients?
International Journal of Clinical Medicine, 2, 588-592 (2011)
Can AHCC improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment?
Journal of Hepatology
Does AHCC have an effect on castration-resistant prostate cancer (CRPC)?
Anti-Cancer Drugs 2009, 20: 215-216
Does AHCC have an effect on patients with advanced breast cancer?
International Journal of Integrative Oncology
Does AHCC have an effect on patients with advanced liver cancer?
Asian Pacific Journal of Allergy and Immunology
Does AHCC have an effect on patients with early stage prostate cancer?
Japanese Journal of Clinical Oncology
Does AHCC have an effect on patients with pancreatic or biliary tract cancer who underwent chemotherapy?
Presented at the 40th APA (American Pancreatic Association)
Does AHCC have an effect on the survival rate of patients with gastric cancer or colon cancer?
Natural Medicine Journal
Does AHCC have immunomodulatory and anticancer effects in cancer patients?
International Journal of Immunotherapy
Does AHCC in combination with GCP extend survival and quality of life in stage IV lung and breast cancer patients?
16th AHCC Research Association, November 2008
What have been some clinical experiences with AHCC and cancer?
Biotherapy 2000; 14(10): 959-964
AHCC® supplementation resulted in the following observations:
- All patients tolerated AHCC® with no added symptoms
- 20 patients reported feeling better and stronger than before at the time of initiation of chemotherapy cycles
- Almost all patients reported better appetites after they started to take AHCC®
- In 12 patients who required blood transfusions before chemotherapy cycles, a decrease in the rate of fall of hemoglobin was observed and only 3 patients subsequently required blood transfusions prior to chemotherapy
- 22 patients has a reduction of chemotherapy side effects like nausea, vomiting, loose motion/ constipation, etc.
- Tumors regressed in 11 patients
- 8 patients stabilized
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Clinical Medicine, 2, 588-592 (2011)
The self-administration of AHCC® resulted in a dramatic PSA decrease within 1 month, which continued to control his disease for over 6 months from initial supplementation with AHCC®.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Journal of Hepatology
The self-administration of AHCC® resulted in a dramatic PSA decrease within 1 month, which continued to control his disease for over 6 months from initial supplementation with AHCC®.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Anti-Cancer Drugs 2009, 20: 215-216
Using the national breast cancer patient registration as reference data, this retrospective study reported the improved prognosis of stage IV patients relative to the national average. Since the stage I-III patients at the center all had recurring cancer while the national average includes both recurring and non-recurring cancers, a meaningful comparison could not be made and the results were not statistically significant.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Integrative Oncology
The following results were reported for patients supplemented with AHCC® when compared with control group:
- A significantly prolonged survival
- Quality of life in terms of mental stability, general physical health status and the ability to have normal activities were significantly improved after 3 months of supplementation
- Serum level of albumin and percentage of lymphocytes in blood, were significantly higher
- Slightly increased levels of total IL-12 and neopterin
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Asian Pacific Journal of Allergy and Immunology
AHCC® supplementation resulted in the following changes:
- Changes in PSA before and after treatment were substantially stable
- In patients for which expectant management had been continued for 6 months or more before the trial, a prolonged PSA doubling time (PSADT) was seen with AHCC® administration – Prior to AHCC®, 12/31 (39%) of patients had PSADT of 120 months or more, and after 6 months of AHCC® administration, 17/31 (55%) had PSADT of 120 months or more. To the lower end, 12/31 (39%) of patients showed a PSADT less than 24 months, and following 6 months of AHCC®, this fell to 9/31 (29%).
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Japanese Journal of Clinical Oncology.
AHCC® supplementation resulted in the following changes compared with the control group:
- The hemoglobin (Hb) level after chemotherapy in AHCC® group was significantly higher
- The taste alteration after chemotherapy in AHCC® group was significantly lower
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Presented at the 40th APA (American Pancreatic Association)
AHCC supplementation resulted in the following difference in survival rate:
- Improved cumulative 5-year survival rates for patients with gastric cancer (stage IA to stage IIIA) compared with other Japanese institutions
- Improved cumulative 5-year survival rates for patients with colon cancer (stage II to stage IIIA) compared with other Japanese institutions
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Natural Medicine Journal
Supplementation with AHCC® had the following results:
- A significant decline in TAA occurred in 8 out of the 11 patients with different types of malignancies
- PSA levels in prostate cancer patients and CA 125 levels in ovarian cancer patients decreased as early as 1 to 2 months and reached normal levels within 1 to 4 months
- 9 out of 11 patients demonstrated marked increase in NK activity as early as 2 weeks after treatment
- The percentages of patients with complete remission were as follows: (i) prostatic (66%); (ii) ovarian (66%). (iii) multiple myeloma (50%); (iv) breast, 33% complete remission and 2 partial
- In vitro studies showed that AHCC® possesses suppressive effects on tumor cell growth
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Immunotherapy
Compared against the survival rates in American Society of Clinical Oncology (ASCO) reference data, this retrospective study reported the following observations:
- 1-year, 2 year and 3-year survival rates for stage IV lung cancer increased to 77.1%, 54.3% and 31.4%, respectively
- Improvement of 1-year to 3-year survival rates and prolongation of median survival time (MST) for lung cancer stage IV
- QOL scores of 35 cases were rated A to C by 77.2% of patients, which contributed to reducing final hospitalization time
- Survival terms for breast cancer patients for 3 years, 4 years and 5 years were 65.6%, 43.8% and 28.1%, respectively
- Mean survival terms for breast cancer patients were 5 years, 2 months after recurrence and 7 years, 11 months after initial diagnosis
- Extension of survival terms was confirmed
- QOL scores on living cases reported a score of A or B (100%), and scores for those who did not survive were A-B (50%) and C (50%)
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
16th AHCC Research Association, November 2008
Health and functional foods are used by progressive cancer patients who hope increased survival time regardless of ambiguous information that includes phrases used to describe these foods, such as “might be effective against cancer.” However, we fear that non evidence-based foods might shorten the lifetime of patients, whose life has already been shortened by cancer. Although our data is retrospective, AHCC® does not increase the risk of shortening the lifetime of cancer patients, at least in the case of hepatocellular carcinoma. Clinical doctors should neither deny alternative medicine without studying, nor accept alternative medicine easily without critical investigation. Based on scientific, rational data, alternative medicine should be applied.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Biotherapy 2000; 14(10): 959-964
Group A was given 1-3g/day of modified arabinoxylane with meals. Group B was given 6000 mg/day of coriolus mushroom. Group C was given 4g/day of antigen-infused dialyzable bovine colostrum/whey extract and Group D was given 3-6g/day of active hexose correlated compound (AHCC®). NK cell activities were assessed before treatment and after an average of 16 weeks of therapy. AHCC® was the only supplement that consistently and statistically increased NK cell activity. The average increase was 249%.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Townsend Letter for Doctors and Patients February/March 2003
Overview
Read More
Published Human Studies
Significance of the Levels of Human Herpes virus 6 in Saliva as a Biomarker in the Reduction of Adverse Effects by AHCC
“Nutrition and Cancer” journal
Experience of the Clinical Use of AHCC® in the Treatment of Severe Forms of Herpes Virus Infections
Dermatovenereology and Gynecology (Almaty, Kazakhstan)
AHCC Induces Production of IL-12 and Interferon -α & γ in Cells from Subjects with Recurring Herpes Simplex Type 1&2 Infections
National Academy of Medical Science of Ukraine (Kiev, Ukraine)
Epstein Barr Herpes virus 4: miRNA and its influence on immune system and risk factors: Diagnostics and Clinical Outcome of a Study
Prevention and Regeneration Clinic (Munich, Germany)
Overview
Published Human Studies
Researchers found that AHCC® downregulates interferon-β (IFN-β) expression and upregulates IFN-γ, which is crucial for activating cytotoxic T cells and promoting viral clearance. Persistent HPV infection is associated with sustained IFN-β production, which can impair effective immune response. By shifting this cytokine balance, AHCC® appears to promote immune recovery and viral elimination. Clinical and in vivo studies showed that AHCC® supplementation led to HPV clearance in a subset of patients and animal models, suggesting a mechanism involving modulation of innate and adaptive immune pathways.
Publication
Frontiers in Oncology
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Frontiers in Oncology
Overview
In addition to being able to fight cancer directly, AHCC also alleviates many of the side effects of chemotherapy, including:
- Hair Loss: Doctors noticed that chemotherapy patients taking AHCC did not lose their hair. Subsequently, an in vivo study found that mice treated with AHCC were protected from chemically induced hair loss.
- Nausea: Clinical studies in Korea and Japan have indicated that AHCC remarkably improves symptoms of nausea and vomiting in cancer patients. (Kenner, p. 18)
- Bone Marrow Suppression: Chemotherapy can inhibit bone marrow function, which is life-threatening because the body’s key immune soldiers — the white blood cells — originate in bone marrow. AHCC has been shown to raise the white blood cell count of cancer patients by about 30%. (Kenner, p. 17)
- Liver Damage: One of the major drawbacks of chemotherapy is that it kills healthy cells in addition to cancer cells. An in vivo study found that while rats given chemotherapy experienced large increases in liver enzymes (indicative of liver damage), those given chemotherapy plus AHCC had normal levels. (Kenner, p. 17)
Read More
Published Human Studies
AHCC® Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer
Frontiers in Immunology
Can AHCC be used in the treatment of head and neck cancer patients?
International Journal of Clinical Medicine, 2, 588-592 (2011)
Can AHCC improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment?
Journal of Hepatology
Does AHCC have an effect on castration-resistant prostate cancer (CRPC)?
Anti-Cancer Drugs 2009, 20: 215-216
Does AHCC have an effect on patients with advanced breast cancer?
International Journal of Integrative Oncology
Does AHCC have an effect on patients with advanced liver cancer?
Asian Pacific Journal of Allergy and Immunology
Does AHCC have an effect on patients with early stage prostate cancer?
Japanese Journal of Clinical Oncology
Does AHCC have an effect on patients with pancreatic or biliary tract cancer who underwent chemotherapy?
Presented at the 40th APA (American Pancreatic Association)
Does AHCC have an effect on the survival rate of patients with gastric cancer or colon cancer?
Natural Medicine Journal
Does AHCC have immunomodulatory and anticancer effects in cancer patients?
International Journal of Immunotherapy
Does AHCC in combination with GCP extend survival and quality of life in stage IV lung and breast cancer patients?
16th AHCC Research Association, November 2008
What have been some clinical experiences with AHCC and cancer?
Biotherapy 2000; 14(10): 959-964
AHCC® supplementation resulted in the following observations:
- All patients tolerated AHCC® with no added symptoms
- 20 patients reported feeling better and stronger than before at the time of initiation of chemotherapy cycles
- Almost all patients reported better appetites after they started to take AHCC®
- In 12 patients who required blood transfusions before chemotherapy cycles, a decrease in the rate of fall of hemoglobin was observed and only 3 patients subsequently required blood transfusions prior to chemotherapy
- 22 patients has a reduction of chemotherapy side effects like nausea, vomiting, loose motion/ constipation, etc.
- Tumors regressed in 11 patients
- 8 patients stabilized
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Clinical Medicine, 2, 588-592 (2011)
The self-administration of AHCC® resulted in a dramatic PSA decrease within 1 month, which continued to control his disease for over 6 months from initial supplementation with AHCC®.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Journal of Hepatology
The self-administration of AHCC® resulted in a dramatic PSA decrease within 1 month, which continued to control his disease for over 6 months from initial supplementation with AHCC®.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Anti-Cancer Drugs 2009, 20: 215-216
Using the national breast cancer patient registration as reference data, this retrospective study reported the improved prognosis of stage IV patients relative to the national average. Since the stage I-III patients at the center all had recurring cancer while the national average includes both recurring and non-recurring cancers, a meaningful comparison could not be made and the results were not statistically significant.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Integrative Oncology
The following results were reported for patients supplemented with AHCC® when compared with control group:
- A significantly prolonged survival
- Quality of life in terms of mental stability, general physical health status and the ability to have normal activities were significantly improved after 3 months of supplementation
- Serum level of albumin and percentage of lymphocytes in blood, were significantly higher
- Slightly increased levels of total IL-12 and neopterin
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Asian Pacific Journal of Allergy and Immunology
AHCC® supplementation resulted in the following changes:
- Changes in PSA before and after treatment were substantially stable
- In patients for which expectant management had been continued for 6 months or more before the trial, a prolonged PSA doubling time (PSADT) was seen with AHCC® administration – Prior to AHCC®, 12/31 (39%) of patients had PSADT of 120 months or more, and after 6 months of AHCC® administration, 17/31 (55%) had PSADT of 120 months or more. To the lower end, 12/31 (39%) of patients showed a PSADT less than 24 months, and following 6 months of AHCC®, this fell to 9/31 (29%).
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Japanese Journal of Clinical Oncology.
AHCC® supplementation resulted in the following changes compared with the control group:
- The hemoglobin (Hb) level after chemotherapy in AHCC® group was significantly higher
- The taste alteration after chemotherapy in AHCC® group was significantly lower
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Presented at the 40th APA (American Pancreatic Association)
AHCC supplementation resulted in the following difference in survival rate:
- Improved cumulative 5-year survival rates for patients with gastric cancer (stage IA to stage IIIA) compared with other Japanese institutions
- Improved cumulative 5-year survival rates for patients with colon cancer (stage II to stage IIIA) compared with other Japanese institutions
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Natural Medicine Journal
Supplementation with AHCC® had the following results:
- A significant decline in TAA occurred in 8 out of the 11 patients with different types of malignancies
- PSA levels in prostate cancer patients and CA 125 levels in ovarian cancer patients decreased as early as 1 to 2 months and reached normal levels within 1 to 4 months
- 9 out of 11 patients demonstrated marked increase in NK activity as early as 2 weeks after treatment
- The percentages of patients with complete remission were as follows: (i) prostatic (66%); (ii) ovarian (66%). (iii) multiple myeloma (50%); (iv) breast, 33% complete remission and 2 partial
- In vitro studies showed that AHCC® possesses suppressive effects on tumor cell growth
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Immunotherapy
Compared against the survival rates in American Society of Clinical Oncology (ASCO) reference data, this retrospective study reported the following observations:
- 1-year, 2 year and 3-year survival rates for stage IV lung cancer increased to 77.1%, 54.3% and 31.4%, respectively
- Improvement of 1-year to 3-year survival rates and prolongation of median survival time (MST) for lung cancer stage IV
- QOL scores of 35 cases were rated A to C by 77.2% of patients, which contributed to reducing final hospitalization time
- Survival terms for breast cancer patients for 3 years, 4 years and 5 years were 65.6%, 43.8% and 28.1%, respectively
- Mean survival terms for breast cancer patients were 5 years, 2 months after recurrence and 7 years, 11 months after initial diagnosis
- Extension of survival terms was confirmed
- QOL scores on living cases reported a score of A or B (100%), and scores for those who did not survive were A-B (50%) and C (50%)
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
16th AHCC Research Association, November 2008
Health and functional foods are used by progressive cancer patients who hope increased survival time regardless of ambiguous information that includes phrases used to describe these foods, such as “might be effective against cancer.” However, we fear that non evidence-based foods might shorten the lifetime of patients, whose life has already been shortened by cancer. Although our data is retrospective, AHCC® does not increase the risk of shortening the lifetime of cancer patients, at least in the case of hepatocellular carcinoma. Clinical doctors should neither deny alternative medicine without studying, nor accept alternative medicine easily without critical investigation. Based on scientific, rational data, alternative medicine should be applied.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Biotherapy 2000; 14(10): 959-964
Group A was given 1-3g/day of modified arabinoxylane with meals. Group B was given 6000 mg/day of coriolus mushroom. Group C was given 4g/day of antigen-infused dialyzable bovine colostrum/whey extract and Group D was given 3-6g/day of active hexose correlated compound (AHCC®). NK cell activities were assessed before treatment and after an average of 16 weeks of therapy. AHCC® was the only supplement that consistently and statistically increased NK cell activity. The average increase was 249%.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Townsend Letter for Doctors and Patients February/March 2003
Overview
Published Human Studies
Can AHCC improve liver function in patients with non-viral, chronic and abnormal liver function conditions?
Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM), July 2010
Does AHCC have an effect on patients with chronic hepatitis C?
Medical News (Thailand)
AHCC® supplementation resulted in the following changes:
- 1 g AHCC® significantly decreased AST, ALT and γ-GT values
- 3 g AHCC® significantly decreased AST, ALT and γ-GT values except the 4-week γ-GT
- AHCC® supplementation had a more dramatic effect on immune cell phenotypes after vaccination of subjects over 60 years old
Publication
Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM), July 2010
AHCC® supplementation resulted in the following changes:
- Although no significant reduction of HCV RNA levels was noticed in AHCC® group patients compared with those of placebo group, subgroup analysis of genotype-3 had a significant HCV RNA decline
- Although the reduction of ALT levels within AHCC® group was not significant, a significant difference was found between AHCC® and placebo groups
- AHCC group ALT levels were stable, while ALT levels increased in placebo group. Such difference was initially noted within the first 6 weeks of the study.
Publication
Medical News (Thailand)
After 12 weeks of supplementation, the percentage change in alanine aminotransferase (ALT) levels was significantly different between the placebo and both AHCC groups (1 g of AHCC® and 3 g of AHCC®). Serum levels of tumor necrosis (p < 0.05) and interleukin-1β ( p < 0.01) were significantly lower, while those of adiponectin were higher in both AHCC® groups than in the placebo group (p < 0.01). AHCC® supplementation for 12 weeks may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced mildly elevated liver enzyme levels. The liver enzyme levels, lipid profiles, insulin resistance, and scores on fatigue and stress-related questionnaires did not show significant differences between the groups (p < 0.05); however, cytokine levels did show significant differences (TNF-α, IL-1β, and adiponectin, p < 0.05). Comparing the percentage changes at 12 weeks as analyzed by a paired t-test, a decrease in liver enzymes in both AHCC groups and a change in IL-1β and adiponectin in the 1-g AHCC® group were found to be statistically significant. When analyzed with ANOVA, the percentage changes of serum levels of inflammatory cytokines, such as TNF-α (p < 0.05) and IL-1β (p < 0.01), were lower in the AHCC® supplementation groups than in the placebo group. Serum levels of adiponectin were higher in both AHCC® groups than in the placebo group (p < 0.05).
Publication
Journal of Nutrition Science Vitaminology
Overview
Published Human Studies
Does AHCC have an effect on immune function of healthy adults aged 50 or greater?
Human Immunology
Does AHCC have an effect on immune response of healthy adults after influenza vaccinations?
Nutrition Research
AHCC® supplementation resulted in the following significant changes compared with base line:
- The frequency of CD4+ and CD8 + T cells producing IFN-γ alone, TNF-α alone or both increased during AHCC intake
- The frequency of such cells remained high even 30 days after discontinuing AHCC®
Publication
Human Immunology
Publication
Nutrition Research
Volunteers supplemented with AHCC® had the following significant changes:
- Greater number of total DCs than at base line and compared with control
- The number of DC1 cells was greater after AHCC® intake than at base line and the AHCC group had a tendency to have higher DC1s than control
- DC2s were significantly increased after 4 weeks compared with control
- The allo-stimulatory activity of DC1s was also increased after intake compared with control as measured by the mixed lymphocyte reaction (MLR)
Publication
Nutrition and Cancer
Overview
There have been numerous studies on AHCC’s effect on the immune system. Is it safe for adults with healthy immune systems? Is it safe to use for immunocompromised individuals? Can AHCC be used as immunotherapy? The following studies address these questions and more when it comes to AHCC’s impact on our immune systems.
Published Human Studies
Is AHCC safe and tolerable in healthy subjects?
Journal of Nutrition Science and Vitaminology
What effect does active hexose correlated compound (AHCC) supplementation have in patients diagnosed with pharmacoresistant epilepsy, to what degree is there a role in the immune system disease pathogenesis, and what is the efficacy of immune therapy?
22nd International Congress on Nutrition and Integrative Medicine
What is the effect of active hexose correlated compound (AHCC) on immune competence in human subjects?
Journal of Evidence-Based Complementary & Alternative Medicine
Laboratory results and adverse events were reported as follows:
- Two subjects (7%) dropped out because of nausea and intolerance of the liquid
- Nausea, diarrhea, bloating, headache, fatigue and foot cramps occurred in a total of 6 subjects (20%) but were mild and transient
- There were no laboratory abnormalities
Publication
Journal of Nutrition Science and Vitaminology
Children with pharmacoresistant epilepsy had decreased mature T lymphocytes (CD3+) and T cells and an imbalance in the subset. The amount of CD3+ T lymphocytes in the epilepsy group was 42.42%±14.65%, which is 82.8% of average. The amount of CD4+ T lymphocytes was 71.6%, and cytotoxic CD8+ was 112.7%. The CD4+/CD8+ lymphocytes subset distribution and regulatory balance had a ratio of 1.28±0.55, which was below average or only 58.6% of the average value. After AHCC® intake, patients had positive changes of peripheral T cell pool (CD3+) and T-helpers (CD4+). They also showed an improvement and increase in the ratio of T suppressors-killers (CD8+) to lymphocytes to 1.4. Due to increases in the CD4+ lymphocytes subset, the immunoregulatory balance of the CD4+ to CD8+ ratio improved. There was a 35% decrease of frequency and intensity of epileptic seizures. The patients’ bodily health status and physiological functions also improved.
Publication
22nd International Congress on Nutrition and Integrative Medicine
Natural killer cell activity significantly increased in both groups during the study period. The natural killer cell number, however, was not altered in the active hexose correlated compound group, while the placebo group showed remarkable decline. In addition, the score of immunological vigor, an index of total immune competence, was maintained in the AHCC® group, although that of the placebo group decreased during the test period.
Publication
Journal of Evidence-Based Complementary & Alternative Medicine
All Published Research
CANCER
AHCC® Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer
Frontiers in Immunology
Can AHCC be used in the treatment of head and neck cancer patients?
International Journal of Clinical Medicine, 2, 588-592 (2011)
Can AHCC improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment?
Journal of Hepatology
Does AHCC have an effect on castration-resistant prostate cancer (CRPC)?
Anti-Cancer Drugs 2009, 20: 215-216
Does AHCC have an effect on patients with advanced breast cancer?
International Journal of Integrative Oncology
Does AHCC have an effect on patients with advanced liver cancer?
Asian Pacific Journal of Allergy and Immunology
Does AHCC have an effect on patients with early stage prostate cancer?
Japanese Journal of Clinical Oncology
Does AHCC have an effect on patients with pancreatic or biliary tract cancer who underwent chemotherapy?
Presented at the 40th APA (American Pancreatic Association)
Does AHCC have an effect on the survival rate of patients with gastric cancer or colon cancer?
Natural Medicine Journal
Does AHCC have immunomodulatory and anticancer effects in cancer patients?
International Journal of Immunotherapy
Does AHCC in combination with GCP extend survival and quality of life in stage IV lung and breast cancer patients?
16th AHCC Research Association, November 2008
What have been some clinical experiences with AHCC and cancer?
Biotherapy 2000; 14(10): 959-964
AHCC® supplementation resulted in the following observations:
- All patients tolerated AHCC® with no added symptoms
- 20 patients reported feeling better and stronger than before at the time of initiation of chemotherapy cycles
- Almost all patients reported better appetites after they started to take AHCC®
- In 12 patients who required blood transfusions before chemotherapy cycles, a decrease in the rate of fall of hemoglobin was observed and only 3 patients subsequently required blood transfusions prior to chemotherapy
- 22 patients has a reduction of chemotherapy side effects like nausea, vomiting, loose motion/ constipation, etc.
- Tumors regressed in 11 patients
- 8 patients stabilized
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Clinical Medicine, 2, 588-592 (2011)
The self-administration of AHCC® resulted in a dramatic PSA decrease within 1 month, which continued to control his disease for over 6 months from initial supplementation with AHCC®.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Journal of Hepatology
The self-administration of AHCC® resulted in a dramatic PSA decrease within 1 month, which continued to control his disease for over 6 months from initial supplementation with AHCC®.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Anti-Cancer Drugs 2009, 20: 215-216
Using the national breast cancer patient registration as reference data, this retrospective study reported the improved prognosis of stage IV patients relative to the national average. Since the stage I-III patients at the center all had recurring cancer while the national average includes both recurring and non-recurring cancers, a meaningful comparison could not be made and the results were not statistically significant.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Integrative Oncology
The following results were reported for patients supplemented with AHCC® when compared with control group:
- A significantly prolonged survival
- Quality of life in terms of mental stability, general physical health status and the ability to have normal activities were significantly improved after 3 months of supplementation
- Serum level of albumin and percentage of lymphocytes in blood, were significantly higher
- Slightly increased levels of total IL-12 and neopterin
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Asian Pacific Journal of Allergy and Immunology
AHCC® supplementation resulted in the following changes:
- Changes in PSA before and after treatment were substantially stable
- In patients for which expectant management had been continued for 6 months or more before the trial, a prolonged PSA doubling time (PSADT) was seen with AHCC® administration – Prior to AHCC®, 12/31 (39%) of patients had PSADT of 120 months or more, and after 6 months of AHCC® administration, 17/31 (55%) had PSADT of 120 months or more. To the lower end, 12/31 (39%) of patients showed a PSADT less than 24 months, and following 6 months of AHCC®, this fell to 9/31 (29%).
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Japanese Journal of Clinical Oncology.
AHCC® supplementation resulted in the following changes compared with the control group:
- The hemoglobin (Hb) level after chemotherapy in AHCC® group was significantly higher
- The taste alteration after chemotherapy in AHCC® group was significantly lower
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Presented at the 40th APA (American Pancreatic Association)
AHCC supplementation resulted in the following difference in survival rate:
- Improved cumulative 5-year survival rates for patients with gastric cancer (stage IA to stage IIIA) compared with other Japanese institutions
- Improved cumulative 5-year survival rates for patients with colon cancer (stage II to stage IIIA) compared with other Japanese institutions
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Natural Medicine Journal
Supplementation with AHCC® had the following results:
- A significant decline in TAA occurred in 8 out of the 11 patients with different types of malignancies
- PSA levels in prostate cancer patients and CA 125 levels in ovarian cancer patients decreased as early as 1 to 2 months and reached normal levels within 1 to 4 months
- 9 out of 11 patients demonstrated marked increase in NK activity as early as 2 weeks after treatment
- The percentages of patients with complete remission were as follows: (i) prostatic (66%); (ii) ovarian (66%). (iii) multiple myeloma (50%); (iv) breast, 33% complete remission and 2 partial
- In vitro studies showed that AHCC® possesses suppressive effects on tumor cell growth
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
International Journal of Immunotherapy
Compared against the survival rates in American Society of Clinical Oncology (ASCO) reference data, this retrospective study reported the following observations:
- 1-year, 2 year and 3-year survival rates for stage IV lung cancer increased to 77.1%, 54.3% and 31.4%, respectively
- Improvement of 1-year to 3-year survival rates and prolongation of median survival time (MST) for lung cancer stage IV
- QOL scores of 35 cases were rated A to C by 77.2% of patients, which contributed to reducing final hospitalization time
- Survival terms for breast cancer patients for 3 years, 4 years and 5 years were 65.6%, 43.8% and 28.1%, respectively
- Mean survival terms for breast cancer patients were 5 years, 2 months after recurrence and 7 years, 11 months after initial diagnosis
- Extension of survival terms was confirmed
- QOL scores on living cases reported a score of A or B (100%), and scores for those who did not survive were A-B (50%) and C (50%)
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
16th AHCC Research Association, November 2008
Health and functional foods are used by progressive cancer patients who hope increased survival time regardless of ambiguous information that includes phrases used to describe these foods, such as “might be effective against cancer.” However, we fear that non evidence-based foods might shorten the lifetime of patients, whose life has already been shortened by cancer. Although our data is retrospective, AHCC® does not increase the risk of shortening the lifetime of cancer patients, at least in the case of hepatocellular carcinoma. Clinical doctors should neither deny alternative medicine without studying, nor accept alternative medicine easily without critical investigation. Based on scientific, rational data, alternative medicine should be applied.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Biotherapy 2000; 14(10): 959-964
Group A was given 1-3g/day of modified arabinoxylane with meals. Group B was given 6000 mg/day of coriolus mushroom. Group C was given 4g/day of antigen-infused dialyzable bovine colostrum/whey extract and Group D was given 3-6g/day of active hexose correlated compound (AHCC®). NK cell activities were assessed before treatment and after an average of 16 weeks of therapy. AHCC® was the only supplement that consistently and statistically increased NK cell activity. The average increase was 249%.
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Townsend Letter for Doctors and Patients February/March 2003
HERPES
Significance of the Levels of Human Herpes virus 6 in Saliva as a Biomarker in the Reduction of Adverse Effects by AHCC
“Nutrition and Cancer” journal
Experience of the Clinical Use of AHCC® in the Treatment of Severe Forms of Herpes Virus Infections
Dermatovenereology and Gynecology (Almaty, Kazakhstan)
AHCC Induces Production of IL-12 and Interferon -α & γ in Cells from Subjects with Recurring Herpes Simplex Type 1&2 Infections
National Academy of Medical Science of Ukraine (Kiev, Ukraine)
Epstein Barr Herpes virus 4: miRNA and its influence on immune system and risk factors: Diagnostics and Clinical Outcome of a Study
Prevention and Regeneration Clinic (Munich, Germany)
HPV
Researchers found that AHCC® downregulates interferon-β (IFN-β) expression and upregulates IFN-γ, which is crucial for activating cytotoxic T cells and promoting viral clearance. Persistent HPV infection is associated with sustained IFN-β production, which can impair effective immune response. By shifting this cytokine balance, AHCC® appears to promote immune recovery and viral elimination. Clinical and in vivo studies showed that AHCC® supplementation led to HPV clearance in a subset of patients and animal models, suggesting a mechanism involving modulation of innate and adaptive immune pathways.
Publication
Frontiers in Oncology
AHCC® supplementation resulted in the following observations:
Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections.
Publication
Frontiers in Oncology
CHEMO SIDE-EFFECTS
Does AHCC alleviate the adverse events in the adjuvant chemotherapy of breast cancer patients?
Presented at the 20th International Congress on Nutrition and Integrative Medicine
Does AHCC have a biological response modifier (BRM)-like effect in advanced-stage cancer patients?
Biotherapy
Is AHCC safe and can AHCC reduce the chemotherapy-induced adverse effects in cancer patients?
Presented at the 17th AHCC Research Association, 2009
Is AHCC safe and can AHCC reduce the chemotherapy-induced adverse effects in cancer patients?
Presented at the 17th AHCC Research Association, 2009
What effect does AHCC have on the reduction of adverse effects in advanced cancer patients on chemotherapy with weakened immune systems experiencing HHV-6 herpes virus infection and liver and blood toxicity?
Nutrition and Cancer
In a study of the beneficial effects of AHCC® supplementation on the alleviation of adverse events in female breast cancer patients receiving chemotherapy, the results found that those receiving AHCC® experienced fewer side-effects, most notably related to neutrophils. Neutrophils make up 50%-75% of white blood cells and are the first immune cells to respond to and arrive at the site of infection. Chemotherapy frequently causes a drastic drop neutrophils (a condition called neutropenia), putting the patient at a greater risk of infection. Patients also to wait for their neutrophil levels to recover before proceeding to their next cycle of chemotherapy which prolongs the length of treatment. So the ability to maintain healthy neutrophil levels not only reduces the risk of infections but also enables women to get through their treatment faster. This is why this latest study showing that AHCC®, a natural compound with an excellent safety profile, can help maintain healthy neutrophil levels is very significant. The researchers at the University of Tokyo retrospectively analyzed 41 consecutive adult patients who underwent adjuvant chemotherapy to see how many of them had to undergo injections of “G-CSF” which are used to stimulate bone marrow production but also entail a number of potential side-effects affecting an estimated 30% of users. They found that those taking AHCC® had significantly lower use of G-CSF drugs than those without the supplement, indicating that AHCC® helped the patients maintain normal neutrophil levels without having to use these side-effect inducing drugs.
Publication
Presented at the 20th International Congress on Nutrition and Integrative Medicine
AHCC® supplementation resulted in the following changes compared with the status before intake:
- Significant improvement in NK cell activity
- Significant improvement in IFN-γ and IL-2 production
- Significant improvement in PS evaluation
Publication
Biotherapy
AHCC® supplementation resulted in the following changes compared with baseline:
- The ratio of NK cells to total lymphocytes increased from 21.67% before taking AHCC® to 26.21% and 26.0% 3 to 6 months after taking AHCC®, respectively
- There was no change in white blood cells, hemoglobin, hematocrit and thrombocyte numbers after taking AHCC®, even though patients were undergoing radiotherapy or chemotherapy
- No adverse effects were observed
Publication
Biotherapy
AHCC® supplementation resulted in the following changes:
- Improved hematologic toxicity (neutropenia) and hepatotoxicity
- A decreased tendency of QLQ-C30 fatigue scale
- A decrease in levels of HHV-6 in saliva by AHCC® Administration
Publication
Presented at the 17th AHCC Research Association, 2009
AHCC® supplementation resulted in the following changes:
- Improved hematologic toxicity (neutropenia) and hepatotoxicity
- A decreased tendency of QLQ-C30 fatigue scale
- A decrease in levels of HHV-6 in saliva by AHCC® Administration
Publication
Presented at the 17th AHCC Research Association, 2009
The DNA levels of herpes virus type 6, often found in people with compromised immune systems and thought to be related to chronic fatigue syndrome, were significantly increased after chemotherapy. AHCC® significantly decreased the levels of HHV-6 in saliva during chemotheraphy, improved AOL scores in the EORTC QLQ-C30 questionnaire and reduced blood and liver toxicity.
Publication
Nutrition and Cancer
It was found that compared with the control group, the AHCC group had significantly fewer neutrophil-related events (odds ratio: 0.30; p = 0.016), significantly lower use of granulocyte colony-stimulating factor, and a higher (although not significant) rate of adverse events associated with c-glutamyl transpeptidase, a liver enzyme.
Publication
The Journal of Alternative and Complementary Medicine
LIVER
Can AHCC improve liver function in patients with non-viral, chronic and abnormal liver function conditions?
Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM), July 2010
Does AHCC have an effect on patients with chronic hepatitis C?
Medical News (Thailand)
AHCC® supplementation resulted in the following changes:
- 1 g AHCC® significantly decreased AST, ALT and γ-GT values
- 3 g AHCC® significantly decreased AST, ALT and γ-GT values except the 4-week γ-GT
- AHCC® supplementation had a more dramatic effect on immune cell phenotypes after vaccination of subjects over 60 years old
Publication
Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM), July 2010
AHCC® supplementation resulted in the following changes:
- Although no significant reduction of HCV RNA levels was noticed in AHCC® group patients compared with those of placebo group, subgroup analysis of genotype-3 had a significant HCV RNA decline
- Although the reduction of ALT levels within AHCC® group was not significant, a significant difference was found between AHCC® and placebo groups
- AHCC group ALT levels were stable, while ALT levels increased in placebo group. Such difference was initially noted within the first 6 weeks of the study.
Publication
Medical News (Thailand)
After 12 weeks of supplementation, the percentage change in alanine aminotransferase (ALT) levels was significantly different between the placebo and both AHCC groups (1 g of AHCC® and 3 g of AHCC®). Serum levels of tumor necrosis (p < 0.05) and interleukin-1β ( p < 0.01) were significantly lower, while those of adiponectin were higher in both AHCC® groups than in the placebo group (p < 0.01). AHCC® supplementation for 12 weeks may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced mildly elevated liver enzyme levels. The liver enzyme levels, lipid profiles, insulin resistance, and scores on fatigue and stress-related questionnaires did not show significant differences between the groups (p < 0.05); however, cytokine levels did show significant differences (TNF-α, IL-1β, and adiponectin, p < 0.05). Comparing the percentage changes at 12 weeks as analyzed by a paired t-test, a decrease in liver enzymes in both AHCC groups and a change in IL-1β and adiponectin in the 1-g AHCC® group were found to be statistically significant. When analyzed with ANOVA, the percentage changes of serum levels of inflammatory cytokines, such as TNF-α (p < 0.05) and IL-1β (p < 0.01), were lower in the AHCC® supplementation groups than in the placebo group. Serum levels of adiponectin were higher in both AHCC® groups than in the placebo group (p < 0.05).
Publication
Journal of Nutrition Science Vitaminology
HEALTHY ADULTS
Does AHCC have an effect on immune function of healthy adults aged 50 or greater?
Human Immunology
Does AHCC have an effect on immune response of healthy adults after influenza vaccinations?
Nutrition Research
AHCC® supplementation resulted in the following significant changes compared with base line:
- The frequency of CD4+ and CD8 + T cells producing IFN-γ alone, TNF-α alone or both increased during AHCC intake
- The frequency of such cells remained high even 30 days after discontinuing AHCC®
Publication
Human Immunology
Publication
Nutrition Research
Volunteers supplemented with AHCC® had the following significant changes:
- Greater number of total DCs than at base line and compared with control
- The number of DC1 cells was greater after AHCC® intake than at base line and the AHCC group had a tendency to have higher DC1s than control
- DC2s were significantly increased after 4 weeks compared with control
- The allo-stimulatory activity of DC1s was also increased after intake compared with control as measured by the mixed lymphocyte reaction (MLR)
Publication
Nutrition and Cancer
IMMUNITY
Is AHCC safe and tolerable in healthy subjects?
Journal of Nutrition Science and Vitaminology
What effect does active hexose correlated compound (AHCC) supplementation have in patients diagnosed with pharmacoresistant epilepsy, to what degree is there a role in the immune system disease pathogenesis, and what is the efficacy of immune therapy?
22nd International Congress on Nutrition and Integrative Medicine
What is the effect of active hexose correlated compound (AHCC) on immune competence in human subjects?
Journal of Evidence-Based Complementary & Alternative Medicine
Laboratory results and adverse events were reported as follows:
- Two subjects (7%) dropped out because of nausea and intolerance of the liquid
- Nausea, diarrhea, bloating, headache, fatigue and foot cramps occurred in a total of 6 subjects (20%) but were mild and transient
- There were no laboratory abnormalities
Publication
Journal of Nutrition Science and Vitaminology
Children with pharmacoresistant epilepsy had decreased mature T lymphocytes (CD3+) and T cells and an imbalance in the subset. The amount of CD3+ T lymphocytes in the epilepsy group was 42.42%±14.65%, which is 82.8% of average. The amount of CD4+ T lymphocytes was 71.6%, and cytotoxic CD8+ was 112.7%. The CD4+/CD8+ lymphocytes subset distribution and regulatory balance had a ratio of 1.28±0.55, which was below average or only 58.6% of the average value. After AHCC® intake, patients had positive changes of peripheral T cell pool (CD3+) and T-helpers (CD4+). They also showed an improvement and increase in the ratio of T suppressors-killers (CD8+) to lymphocytes to 1.4. Due to increases in the CD4+ lymphocytes subset, the immunoregulatory balance of the CD4+ to CD8+ ratio improved. There was a 35% decrease of frequency and intensity of epileptic seizures. The patients’ bodily health status and physiological functions also improved.
Publication
22nd International Congress on Nutrition and Integrative Medicine
Natural killer cell activity significantly increased in both groups during the study period. The natural killer cell number, however, was not altered in the active hexose correlated compound group, while the placebo group showed remarkable decline. In addition, the score of immunological vigor, an index of total immune competence, was maintained in the AHCC® group, although that of the placebo group decreased during the test period.
Publication
Journal of Evidence-Based Complementary & Alternative Medicine
Published Research
Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses
Cancer Immunology Immunother
AHCC®‘s Beneficial Immuno Modulation Effects in the Thymus
Endocrine Regulations
Anti-Tumor Effects of Genistein Combined Polysaccharide (GCP) and Active Hexose Correlated Compound (AHCC®)
Biotherapy 2001; 15(3):379-382
Application of New Immunotherapy Using AHCC® for Animal Disease
Presentation
Augmentation of canine cellular immune response by administration of AHCC®
Presentation
Combination therapy of Active Hexose Correlated Compound AHCC® on Thymic Apoptosis Induced by Dexometasone in the Rat
Endocrine Regulations 2006
Combination therapy of Active Hexose Correlated Compound AHCC® plus UFT significantly Reduces The metastasis of Rat Mamary Adenocarcinoma
Anti-Cancer Drugs
Evaluation of Active Hexose Correlated Compound for the Prevention or Delay of Tumor Growth in Human Cervical Cancer Xenograft Model
Cancer Prevention Research
H-2 Haplotype-Dependent Serum IL-12 in Tumor-Bearing Mice Treated with Various Mycelial Extracts
Study Abstract
Published Research
Ameliorative Effect of AHCC for Anticancer Drug Induced Side Effects
Amino up Chemical CO., LTD
Evaluation of Active Hexose Correlated Compound AHCC Hepatic Metabolism and Potential for Drug Interactions with Chemotherapy Agents
Journal of Social Integral Oncology
The Influence of AHCC on Cisplatin-Evoked Chemotherapeutic and Side Effects in Tumor-Bearing Mice
Toxicology and Applied Pharmacology
Published Research
AHCC Protects the Liver
Natural Medicine
Effect of AHCC on the Production of Nitric Oxide in Hepatocytes
Journal of Parenteral and Enteral Nutrition
Supressive Effects of AHCC on the Increased Activity of Hepatic and Renal Ornithine Decarboxylase Induced by Oxidative Stress
Life Sciences
Overview
- Decreased severity of infection
- Shortened recovery time
- Increased survival
Published Research
AHCC® enhances resistance to Covid-19 infection
The Journal of Nutrition, Nutritional Immunology
Active Hexose Correlated Compound Enhanced the Immune Function of Mice in the Hindlimb-Unloading Model of Spaceflight Conditions
Journal of Applied Physiology
AHCC Activate Immune Function to Decrease Bacterial Load in Murine Model of Intramuscular Infectio
The American Journal of Surgery
AHCC can Reduce the Severity of Influenza
The Journal of Nutrition, Nutritional Immunology
AHCC improves the antibody response to the influenza B vaccine
Department of Food Science and Human Nutrition, Michigan State University
AHCC Enhances Resistance to Infection in a Mouse Model of Surgical Wound Infection
Surgical Infections
AHCC Enhances Resistance to Klebsiella Pneumoniae Infection in Mice
Journal of Applied Physiology
AHCC Normalizes Immune Function
AHCC Research 9th Symposium
AHCC on Immobilization Stress in Rat: Beneficial Effects of AHCC
Dokkyo Journal of Medical Science
AHCC Protects the Thymus Gland
Endocrine Regulations
AHCC Significantly Raised the Survival Rate of Avian Flu
15th International Symposium of the AHCC Research Association
Independant Comparison of NK Activity in AHCC and MGN-3
Hokkaido University
Low-dose supplementation with active hexose correlated compoundimproves the immune response to acute influenza infection inC57BL/6 mice
Department of Biology Drexel University
Nutritional Food Active Hexose Correlated Compound AHCC Enhances Resistance Against Bird Flu
Japanese Journal of Complimentary and Alternative Medicine
Oral Administration of Active Hexose Correlated Compound Enhances Host Resistance to WestNile Encephalitis in Mice
Journal of Nutrition Science and Vitaminology
Role of AHCC in Helping to Build up Immunity
Japanese Journal of Complementary and Alternative Medicine
Supplementation with active hexose correlated compound increases survival following infectious challenge in mice
Emerging Science
Supplementation with Active Hexose Correlated Compound Increases the Innate Immune response of young mice to Primary Influenza Infection
Journal of Nutrition
Overview
AHCC appears to have several benefits for diabetics. A small human clinical trial conducted in Japan found that all 13 diabetic patients enrolled in the study experienced a significant drop in blood glucose and glycohemoglobin levels after taking AHCC for six months. (Kenner, p. 21)
AHCC’s blood-sugar lowering effect was also observed in animal research. Diabetes was induced in rats through injection with the chemical streptozotocin (STZ). Among untreated (control) animals, blood glucose levels increased, insulin levels decreased, and insulin-secreting cells were damaged. Among AHCC-treated rats, however, blood glucose levels decreased, insulin levels increased, and there was little damage to insulin-secreting cells.
Published Research
Protective Effects of AHCC® on the onset of diabetes induced by Streptozotocin in the Rat
Dokkyo University School of Medicine
Overview
While many people associate inflammation with arthritis, few realize it is one of the underlying contributors to a number of different diseases, from asthma to heart disease to Alzheimer’s. In acute situations, such as sickness or injury, inflammation is helpful because it helps the body eliminate pathogens. When inflammation becomes chronic, however, it can destroy healthy tissue. Research shows that AHCC has a profound anti-inflammatory effect.
One study found that AHCC administration attenuated inflammation in rats with colitis (inflammation of the colon) at a level equal to that of the anti-inflammatory drug sulfasalazine. Another study observed that AHCC protected rats from the damaging effects of peritonitis (inflammation of the peritoneum, the membrane that lines the abdominal cavity). (Kenner, p. 23)
Published Research
Suppressive Efect of AHCC® on acute inflamation
Faculty of Pharmaceutical Sciences, Teiko University
Overview
It is widely recognized that stress plays a major role in the etiology of many diseases. When people and animals are under stress, several things happen: The production of stress hormones such as adrenalin and corticosteroids increases, uric acid production increases, and blood sugar rise.
A study in rats that had been stressed through immobilization found that AHCC mediated the stress response, keeping levels of stress hormones, uric acid, and blood sugar normal.
Other in vivo studies have shown that as a potent antioxidant, AHCC may also protect against disorders caused by oxidative stress (cellular stress caused by free radicals).
Published Research
AHCC® on Immobilization Stress in the Rat
Department of Biochemistry, Dokkyo University School of Medicine
All Published Research
CANCER
Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses
Cancer Immunology Immunother
AHCC®‘s Beneficial Immuno Modulation Effects in the Thymus
Endocrine Regulations
Anti-Tumor Effects of Genistein Combined Polysaccharide (GCP) and Active Hexose Correlated Compound (AHCC®)
Biotherapy 2001; 15(3):379-382
Application of New Immunotherapy Using AHCC® for Animal Disease
Presentation
Augmentation of canine cellular immune response by administration of AHCC®
Presentation
Combination therapy of Active Hexose Correlated Compound AHCC® on Thymic Apoptosis Induced by Dexometasone in the Rat
Endocrine Regulations 2006
Combination therapy of Active Hexose Correlated Compound AHCC® plus UFT significantly Reduces The metastasis of Rat Mamary Adenocarcinoma
Anti-Cancer Drugs
Evaluation of Active Hexose Correlated Compound for the Prevention or Delay of Tumor Growth in Human Cervical Cancer Xenograft Model
Cancer Prevention Research
H-2 Haplotype-Dependent Serum IL-12 in Tumor-Bearing Mice Treated with Various Mycelial Extracts
Study Abstract
CHEMO
Ameliorative Effect of AHCC for Anticancer Drug Induced Side Effects
Amino up Chemical CO., LTD
Evaluation of Active Hexose Correlated Compound AHCC Hepatic Metabolism and Potential for Drug Interactions with Chemotherapy Agents
Journal of Social Integral Oncology
The Influence of AHCC on Cisplatin-Evoked Chemotherapeutic and Side Effects in Tumor-Bearing Mice
Toxicology and Applied Pharmacology
LIVER
AHCC Protects the Liver
Natural Medicine
Effect of AHCC on the Production of Nitric Oxide in Hepatocytes
Journal of Parenteral and Enteral Nutrition
Supressive Effects of AHCC on the Increased Activity of Hepatic and Renal Ornithine Decarboxylase Induced by Oxidative Stress
Life Sciences
INFECTION
AHCC® enhances resistance to Covid-19 infection
The Journal of Nutrition, Nutritional Immunology
Active Hexose Correlated Compound Enhanced the Immune Function of Mice in the Hindlimb-Unloading Model of Spaceflight Conditions
Journal of Applied Physiology
AHCC Activate Immune Function to Decrease Bacterial Load in Murine Model of Intramuscular Infectio
The American Journal of Surgery
AHCC can Reduce the Severity of Influenza
The Journal of Nutrition, Nutritional Immunology
AHCC improves the antibody response to the influenza B vaccine
Department of Food Science and Human Nutrition, Michigan State University
AHCC Enhances Resistance to Infection in a Mouse Model of Surgical Wound Infection
Surgical Infections
AHCC Enhances Resistance to Klebsiella Pneumoniae Infection in Mice
Journal of Applied Physiology
AHCC Normalizes Immune Function
AHCC Research 9th Symposium
AHCC on Immobilization Stress in Rat: Beneficial Effects of AHCC
Dokkyo Journal of Medical Science
AHCC Protects the Thymus Gland
Endocrine Regulations
AHCC Significantly Raised the Survival Rate of Avian Flu
15th International Symposium of the AHCC Research Association
Independant Comparison of NK Activity in AHCC and MGN-3
Hokkaido University
Low-dose supplementation with active hexose correlated compoundimproves the immune response to acute influenza infection inC57BL/6 mice
Department of Biology Drexel University
Nutritional Food Active Hexose Correlated Compound AHCC Enhances Resistance Against Bird Flu
Japanese Journal of Complimentary and Alternative Medicine
Oral Administration of Active Hexose Correlated Compound Enhances Host Resistance to WestNile Encephalitis in Mice
Journal of Nutrition Science and Vitaminology
Role of AHCC in Helping to Build up Immunity
Japanese Journal of Complementary and Alternative Medicine
Supplementation with active hexose correlated compound increases survival following infectious challenge in mice
Emerging Science
Supplementation with Active Hexose Correlated Compound Increases the Innate Immune response of young mice to Primary Influenza Infection
Journal of Nutrition
DIABETES
Protective Effects of AHCC® on the onset of diabetes induced by Streptozotocin in the Rat
Dokkyo University School of Medicine
INFLAMATION
Suppressive Efect of AHCC® on acute inflamation
Faculty of Pharmaceutical Sciences, Teiko University
STRESS
AHCC® on Immobilization Stress in the Rat
Department of Biochemistry, Dokkyo University School of Medicine
Books

This is How Much AHCC Can Fight Against Cancer!

Foundation and Clinical Study of AHCC

Triumph Over Cancer, Diabetes and Liver Disease!

Conquered Cancer With AHCC

Consumer Books AHCC

Dr. Fred Pescatore – Clinician Books

AHCC
Description
Please inquire about other books using the button below